Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes
Authors:
- 7 August 2012
- journal article
- research article
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 31 (1) , 89-95
Abstract
Evidence suggests that bone quality is poorer and fracture risk is higher in patients with diabetes, even those with normal bone mineral density. The aim of this study was to determine the effects of raloxifene on lipid, bone, and glucose metabolism in postmenopausal women with type 2 diabetes. The study subjects (144 postmenopausal women aged less than 80 years with type 2 diabetes) were randomly assigned into three groups: no medication, alfacalcidol 1 μg/day, or raloxifene hydrochloride 60 mg/day. The primary endpoint was the change in LDL-C at 6 months. Raloxifene significantly decreased the levels of bone metabolism markers NTX and BAP at 6 months in patients with diabetes. The primary endpoint, LDL-C at 6 months, was significantly lower in the raloxifene group than in the other two groups. However, percent changes in HDL-C were not significantly different among the three groups. Although glucose metabolism was unaffected, homocysteine, a bone quality marker, was significantly decreased at 6 months in the raloxifene group. The percent improvement in LDL-C did not correlate with percent improvement in any bone metabolism or bone quality markers. Raloxifene, unlike estrogen, improved LDL-C and decreased homocysteine, indicating that raloxifene can potentially improve LDL-C as well as bone quality in postmenopausal women with type 2 diabetes.Keywords
This publication has 26 references indexed in Scilit:
- Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trialBMC Medicine, 2011
- Vitamin D and adipogenesis: new molecular insightsNutrition Reviews, 2008
- Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone massBone, 2007
- Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathwaysBone, 2007
- Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal WomenNew England Journal of Medicine, 2006
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Raloxifene Does Not Affect Insulin Sensitivity or Glycemic Control in Postmenopausal Women with Type 2 Diabetes Mellitus: A Randomized Clinical TrialThe Journal of Clinical Endocrinology & Metabolism, 2002
- Osteoporosis Prevention, Diagnosis, and TherapyJAMA, 2001
- Older Women with Diabetes Have an Increased Risk of Fracture: A Prospective StudyThe Journal of Clinical Endocrinology & Metabolism, 2001
- Advanced Glycation Endproducts Stimulate Interleukin-6 Production by Human Bone-Derived CellsJournal of Bone and Mineral Research, 1997